Challenges in validating candidate therapeutic targets in cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29417929.
- Also identified by DOI 10.7554/eLife.32402 and PMC identifier 5805407.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
More than 30 published articles have suggested that a protein kinase called MELK is an attractive therapeutic target in human cancer, but three recent reports describe compelling evidence that it is not. These reports highlight the caveats associated with some of the research tools that are commonly used to validate candidate therapeutic targets in cancer research.
Medical subject headings
- Antineoplastic Agents
- Drug Discovery
- Neoplasms
- Protein Serine-Threonine Kinases